SCHEMBL3760728

SCHEMBL3760728

CCOC(=O)CNC(=O)c1c(O)ccc2nc(-c3ccc(F)cc3)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 4/20 0.39
EGLN3 Q9H6Z9 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 3/20 0.39
ALOX15 P16050 2/20 0.39
CASP1 P29466 2/20 0.39
GAA P10253 1/20 0.39
CASP7 P55210 1/20 0.39
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
BID P55957 1/20 0.39
BCL2A1 Q16548 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518478 0.90 EGLN3 (0.50) HPGDKMT2AMEN1ALDH1A1EGLN3
SCHEMBL3766318 0.89 MAPT (0.39) HPGDKMT2AMEN1POLBALDH1A1
SCHEMBL3521384 0.89 CASP1 (0.49) HPGDKMT2ANPSR1MEN1ALDH1A1
SCHEMBL3521148 0.89 EGLN3 (0.46) HPGDKMT2AMEN1ALDH1A1EGLN3
SCHEMBL3521074 0.88 PLA2G2A (0.41) HPGDKMT2ANPSR1POLBALDH1A1
SCHEMBL3759035 0.87 CASP1 (0.40) HPGDALDH1A1EGLN3KDM4EHSD17B10
SCHEMBL3521070 0.87 EGLN1 (0.43) HPGDKMT2APOLBALDH1A1EGLN3
SCHEMBL3761595 0.86 L3MBTL1 (0.40) HPGDPOLBALDH1A1EGLN3L3MBTL1
SCHEMBL3758527 0.86 EGLN3 (0.54) EGLN3MAPK1EGLN1ABL1
SCHEMBL3761570 0.85 EGLN3 (0.45) HPGDKMT2AMEN1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 HPGD 51/4885HTT 2129/4885KMT2A 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.